摘要
目的 分析血液透析(MHD)患者继发性甲状旁腺功能亢进(SHPT)采取骨化三醇+西那卡塞治疗的效果。方法 选取2020年1月至2023年1月收治的60例MHD并发SHPT患者,随机分为观察组(骨化三醇+西那卡塞)和对照组(西那卡塞)各30例,对比效果。结果 治疗前后,两组患者临床症状发生情况、肾功能指标组间对比差异均无统计学意义(P>0.05)。治疗前,两组实验室指标、甲状旁腺大小、甲状腺激素水平对比差异无统计学意义(P>0.05);治疗后,观察组实验室指标优于对照组,甲状旁腺体积小于对照组,甲状腺激素水平低于对照组(均P<0.05)。结论 骨化三醇与西那卡塞联合对MHD并发SHPT患者治疗可有效改善临床症状,抑制病情发展,价值较高。
Objective To analyze the effectiveness of calcitriol+senecase treatment for secondary hyperparathyroidism(SHPT)in hemodialysis(MHD)patients.Methods Sixty patients with MHD complicated with SHPT admitted from January 2020 to January 2023 were randomly divided into an observation group(calcitriol+sinacase)and a control group(sinacase),with 30 patients in each group,and the effects were compared.Results Before and after treatment,the differences in the occurrence of clinical symptoms and renal function indicators between the two groups were not statistically significant(P>0.05).Before treatment,there was no statistically significant difference in the comparison of laboratory indexes,parathyroid gland size,and thyroid hormone level between the two groups(P>0.05);after treatment,laboratory indexes of the observation group were better than those of the control group,the parathyroid gland volume was smaller than that of the control group,and the level of thyroid hormone was lower than that of the control group(all P<0.05).Conclusions The combination of calcitriol and senacase in the treatment of MHD complicated with SHPT can effectively improve clinical symptoms,inhibit disease progression,and have high value.
作者
魏芝薇
查白
周威
WEI Zhiwei;ZHA Bai;ZHOU Wei(Nanjing Gaochun People's Hospital,Nanjing 211300,China)
出处
《中国医药指南》
2024年第4期76-79,共4页
Guide of China Medicine
